Doxepin Use in Patients with Obstructive Sleep Apnea
Low-dose doxepin (3-6 mg) can be used cautiously in patients with obstructive sleep apnea (OSA) for insomnia treatment, but only after OSA is adequately treated with CPAP or other appropriate therapy, and with careful monitoring for respiratory depression.
Key Clinical Considerations
Safety Profile in OSA
The FDA drug label explicitly warns that caution is advised if signs/symptoms of compromised respiratory function (e.g., asthma, COPD, sleep apnea) are present 1. This is a critical contraindication that cannot be ignored. Traditional higher-dose tricyclic antidepressants can worsen respiratory function through:
- Central nervous system depression
- Reduced upper airway muscle tone
- Potential worsening of apneic events
When Doxepin May Be Appropriate
Doxepin is specifically recommended for sleep maintenance insomnia at low doses (3-6 mg) 2. The 2017 American Academy of Sleep Medicine guideline provides a weak recommendation for doxepin use, showing:
- Mean improvement in total sleep time: 26-32 minutes versus placebo
- Mean reduction in wake after sleep onset: 22-23 minutes versus placebo
- Small-to-moderate improvement in sleep quality 2
The 2020 VA/DoD guideline suggests considering low-dose doxepin (3 or 6 mg) for patients who are unable or unwilling to receive CBT-I, with the important caveat that the risk for suicidal ideation associated with low-dose doxepin as a hypnotic agent is unknown 3.
Clinical Algorithm for Use
Step 1: Ensure OSA is adequately treated
- Patient must be established on CPAP therapy with good adherence, OR
- OSA has been successfully treated with oral appliance therapy or surgery
- Verify treatment efficacy with follow-up sleep study or clinical assessment
Step 2: Confirm insomnia persists despite OSA treatment
- Document residual insomnia symptoms (difficulty maintaining sleep)
- Rule out other causes: poor sleep hygiene, medications, comorbid conditions
- Consider cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment
Step 3: If pharmacotherapy is necessary
- Start with doxepin 3 mg at bedtime (not the 25-50 mg antidepressant doses)
- May increase to 6 mg if 3 mg is ineffective after 1-2 weeks
- Never use higher doses - the evidence and safety profile only support 3-6 mg 2, 3, 4
Step 4: Monitoring requirements
- Follow-up within 1 week to assess for:
- Excessive daytime sedation
- Morning confusion or "hangover" effect
- Worsening of OSA symptoms (increased snoring, witnessed apneas, daytime sleepiness)
- Anticholinergic effects (dry mouth, constipation, urinary retention)
- Consider repeat sleep study if OSA symptoms worsen
- Regular follow-up every few weeks initially, then every 3-6 months 5
Important Caveats and Pitfalls
Age considerations: Elderly patients are at higher risk for adverse effects. The FDA label specifically warns that sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of doxepin and observed closely 1. Start with 3 mg and monitor carefully.
Comorbid insomnia and OSA (COMISA): This condition affects 29-67% of patients with insomnia who have an AHI > 5 6. Recent evidence suggests that combination therapy including both CBT-I and OSA treatment resulted in greater improvements than either alone 6. This underscores that pharmacotherapy should be adjunctive, not primary treatment.
Alternative considerations: If the patient has difficulty falling asleep rather than staying asleep, consider:
- Ramelteon 8 mg (melatonin receptor agonist) - safer respiratory profile 2
- Non-benzodiazepine BZRAs (zolpidem, eszopiclone) - though these also require caution in OSA 3
Absolute contraindications:
- Uncontrolled or untreated OSA
- Severe OSA with significant hypoxemia
- Concurrent use of other CNS depressants or alcohol
- Obesity hypoventilation syndrome without adequate treatment
What NOT to Do
Do not use benzodiazepines - The 2020 VA/DoD guideline explicitly advises against benzodiazepines for chronic insomnia disorder, citing risks of dependency, falls, cognitive impairment, and hypoventilation in patients with respiratory conditions including sleep apnea 3.
Do not use trazodone - Despite common off-label use, the 2017 AASM guideline suggests clinicians NOT use trazodone for insomnia 2, and one study showed it increased arousals 7.
Do not use antihistamines - Not recommended due to anticholinergic effects and rapid tolerance 3.
Monitoring for Treatment Failure or Complications
If the patient develops any of the following, discontinue doxepin immediately:
- Increased daytime sleepiness beyond baseline
- Worsening snoring or witnessed apneas
- Morning headaches (sign of nocturnal hypercapnia)
- Cognitive impairment or confusion
- Respiratory depression
The evidence consistently shows that non-pharmacologic interventions (CBT-I) are more effective than pharmacologic therapies for chronic insomnia 3. Doxepin should be viewed as a short-term adjunct in carefully selected patients with treated OSA, not as a long-term solution.